DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Altoprev (Lovastatin) - Published Studies

 
 



Altoprev Related Published Studies

Well-designed clinical trials related to Altoprev (Lovastatin)

Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. [2013]

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]

Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease. [2011.02]

Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]

Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. [2010.01]

Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. [2010]

Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial. [2009.07]

Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. [2009.06.18]

The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. [2007.09]

Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. [2006.05]

Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. [2005.12]

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. [2005.11]

Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. [2005.09]

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. [2004.09]

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. [2004.06]

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. [2004.05.24]

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. [2004.01.01]

Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia. [2004.01]

A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. [2003.11]

Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. [2003.07.23]

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). [2003.03.15]

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. [2003.03]

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. [2003.02.15]

Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. [2003.01]

A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia. [2002.06]

Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. [2002.05]

Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. [2002.04.01]

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. [2002.03.15]

Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. [2002.02]

Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. [2002.01]

A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. [2002.01]

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. [2002]

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. [2001.12]

Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. [2001.10]

Effects of lovastatin and pravastatin on cognitive function in military aircrew. [2001.09]

Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. [2001.06]

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. [2001.06]

Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. [2001.06]

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. [2001.05.01]

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. [2001.05]

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. [2000.12.01]

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. [2000.12]

Effects of lovastatin on cognitive function and psychological well-being. [2000.05]

Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. [1999.10]

Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT) [1999.10]

Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. [1999.07.20]

Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation. [1999.06]

Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. [1999.06]

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). [1999.05.15]

Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia. [1999.03]

Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. [1999.02.01]

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. [1999.01.13]

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. [1999.01]

Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. [1999]

Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. [1998.12]

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. [1998.11]

The interaction of diltiazem with lovastatin and pravastatin. [1998.10]

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. [1998.09]

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. [1998.07]

Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. [1998.07]

Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. [1998.06]

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. [1998.05.27]

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. [1998.04]

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [1998.03.01]

Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. [1998.03]

Effects of lovastatin on the immune system. [1997.11.15]

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. [1997.10.01]

Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. [1997.10]

Lovastatin increases exercise-induced skeletal muscle injury. [1997.10]

Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. [1997.09]

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. [1997.09]

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. [1997.07.15]

Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. [1997.06.30]

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. [1997.06.01]

The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. [1997.04]

A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. [1997.02]

[A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia] [1996.12]

Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention. [1996.09.26]

Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. [1996.08.15]

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. [1996.07]

[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia] [1996.05.25]

Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. [1996.05]

Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. [1996.05]

Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. [1996.03.15]

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. [1996.03.15]

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. [1996.03.01]

Lovastatin lowers serum cholesterol levels in non-insulin-dependent diabetes mellitus patients without altering their insulin sensitivity. [1996.03]

Costs of coronary restenosis (Lovastatin Restenosis Trial). [1996.01.15]

Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin. [1995.11]

A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia. [1995.09]

The effect of supplemental dietary fat on plasma cholesterol levels in lovastatin-treated hypercholesterolemic patients. [1995.09]

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. [1995.07.15]

The effect of lovastatin on early restenosis. [1995.06]

Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. [1995.05]

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. [1995.04]

Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. [1995.04]

Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. [1995.02]

Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. [1995.02]

Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. [1995.01.01]

Physiologic mechanisms of action of lovastatin in nephrotic syndrome. [1995.01]

Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). [1994.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014